Research Article
Immunological Evaluation for Personalized Interventions in Children with Tuberculosis: Should It Be Routinely Performed?
Table 1
Clinical and demographical data of TB patients.
| | Subjects | Age | Sex | BMI (kg/m2) | TB type | Concomitant infections | TB treatment | Treatment duration |
| | Patient 1 | 14 | F | 15.2 | Pulmonary | Unknown fungus | HRZE | 18 months | | Patient 2 | 5 | M | 13.6 | Pulmonary | M. catarrhalis | HRZE | 6 months | | Patient 3 | 12 | F | 19.3 | Lymph node | No | HRZE | 2 years | | Patient 4 | 16 | F | 18.5 | Bone | No | HRZE | 2 years | | Patient 5 | 13 | F | 20.3 | Lymph node (RR) | No | H, Lfx, Dlm, Lzd, Cfz | 18 months | | Patient 6 | 1 | F | 14.7 | Pulmonary | Rhinovirus | HRZE | 6 months | | Patient 7 | 1 | F | 11.5 | Pulmonary | Flu A H1N1 | HRZE | 6 months | | Cladophialophora spp. | | Patient 8 | 4 | F | 13.2 | Pulmonary | Penicillium spp. | HRZE | 6 months |
|
|
TB: tuberculosis; RR: rifampin resistant; H: isoniazid; R: rifampin; Z: pyrazinamide; E: ethambutol; Lfx: levofloxacin; Dlm: delamanid; Lzd: linezolid; Cfz: clofazimine.
|
